Your session is about to expire
← Back to Search
Anthelmintic
Pyrvinium Pamoate for Pancreatic Cancer
Phase 1
Recruiting
Led By Harish Lavu, MD
Research Sponsored by Thomas Jefferson University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients must have an estimated life expectancy of > 3 months, and Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 weeks
Awards & highlights
Study Summary
This trial is testing a drug to treat pancreatic cancer that cannot be removed by surgery. The drug may help patients live longer.
Who is the study for?
This trial is for patients with pancreatic ductal adenocarcinoma that can't be surgically removed. Participants must not be on recent anticancer therapy, agree to use contraception, and have a life expectancy over 3 months with good performance status. Excluded are pregnant or breastfeeding individuals, those with chronic bowel conditions, kidney or liver function impairment.Check my eligibility
What is being tested?
The study tests the safety and optimal dosage of Pyrvinium Pamoate (PP) in treating non-resectable pancreatic cancer. It aims to determine if PP can slow tumor growth and extend patient survival.See study design
What are the potential side effects?
While specific side effects for Pyrvinium Pamoate in this context aren't detailed, common reactions may include digestive issues, allergic reactions to its components, and potential impacts on liver or kidney functions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am expected to live more than 3 months and can carry out all my self-care activities.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 30 days from last dose
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 30 days from last dose
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Incidence of dose limited toxicity (DLT)
Secondary outcome measures
Bioavailability of PP
Fatty tissue accumulation of PP
Profile of pyrvinium pamoate (PP)
Trial Design
1Treatment groups
Experimental Treatment
Group I: Treatment (pyrvinium pamoate)Experimental Treatment1 Intervention
Patients receive pyrvinium pamoate PO QD for 3 days in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.
Find a Location
Who is running the clinical trial?
Thomas Jefferson UniversityLead Sponsor
445 Previous Clinical Trials
145,696 Total Patients Enrolled
Harish Lavu, MDPrincipal InvestigatorThomas Jefferson University
5 Previous Clinical Trials
1,667 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My kidney function is impaired.I haven't started neoadjuvant therapy or finished it at least 3 weeks before starting PP therapy.I am not currently on cancer treatment and haven't been for the last 3 weeks.I have a long-term bowel condition like IBD.I agree to use birth control during and for 30 days after the study.I am expected to live more than 3 months and can carry out all my self-care activities.I will use condoms during the trial.I am diagnosed with pancreatic cancer and considered a candidate for surgery.I cannot have surgery on my pancreas due to my current health condition.My liver isn't working well, with high enzyme levels and bilirubin, and low albumin.My liver function tests are within normal ranges.You have had allergic reactions to the study product called pyrvinium pamoate/pyrvinium embonate (Molevac).I am a woman of childbearing age and will use birth control or condoms during the study.
Research Study Groups:
This trial has the following groups:- Group 1: Treatment (pyrvinium pamoate)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Does Pyrvinium Pamoate have any harmful side effects?
"Given that this is a Phase 1 trial with limited data surrounding its safety and efficacy, our team at Power has given Pyrvinium Pamoate a score of 1."
Answered by AI
Is there a significant body of scientific research on Pyrvinium Pamoate?
"At the moment, there is only 1 active clinical trial for Pyrvinium Pamoate. This is a Phase 3 trial. The majority of research surrounding Pyrvinium Pamoate is conducted in Philadelphia, with 1 other location running similar studies."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger